Table IV.
Response to treatment | TFTH + BV, n=17 (%) |
---|---|
Complete response (CR) | 0 (0) |
Partial response (PR) | 0 (0) |
Stable disease (SD) | 12 (71) |
Progressive disease (PD) | 5 (29) |
Not evaluable (NE) | 0 (0) |
Overall response (CR + PR) | 0 (0) |
Disease control (CR + PR + SD) | 12 (71) |
TFTD, trifluridine and tipiracil hydrochloride; BV, bevacizumab.